We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Glenmark Ordered to Pay $16 Million for At-Risk Launch of Tarka
Glenmark Ordered to Pay $16 Million for At-Risk Launch of Tarka
January 18, 2011
A federal court jury has upheld Sanofi-Aventis and Abbott Laboratories’ patent on the anti-hypertensive drug Tarka and ordered Glenmark Pharmaceuticals to pay $16 million in damages following its at-risk launch of a generic version of the drug.